Infant Probiotics Trials Show Results That Aren't Clear
- 01. Clinical Evidence on Infant Probiotics for Gas Relief
- 02. Landmark Infant Probiotic Trials
- 03. Probiotics and Long-Term Gas or Pain Outcomes
- 04. Nutritional Interventions and Symptom Domains
- 05. Limitations and Inconsistencies in the Evidence
- 06. Key Clinical Trials and Their Reported Outcomes
- 07. How Pediatric Guidelines View Probiotics for Gas
- 08. Comparing Probiotics and Traditional Gas Treatments
- 09. Takeaways for Parents and Clinicians
- 10. Common Questions About Infant Probiotics and Gas
- 11. Are there any infant probiotics that are clearly ineffective for gas?
Clinical Evidence on Infant Probiotics for Gas Relief
Clinical trials on infant probiotics for gas and crying relief show statistically significant but inconsistent benefits, especially with specific strains such as Limosilactobacillus reuteri DSM 17938, while other studies report minimal or no effect compared with placebo or simethicone. In many randomized controlled trials, infants receiving active probiotics averaged roughly 30-60 minutes less daily crying by day 21, and some meta-analyses report a 30-50 percent greater likelihood of symptom improvement versus control groups, yet effect sizes vary by study design, age, feeding pattern, and outcome measure.
Overall, the evidence suggests that certain probiotic strains can modestly reduce gas-related fussiness and colic-type crying in some infants, but results are not universally reproducible and safety remains a key consideration before routine use.
Landmark Infant Probiotic Trials
In a 2011 randomized, double-blind trial, 50 exclusively breastfed colicky infants aged 2-16 weeks received either 5 drops of L. reuteri DSM 17938 (about 100 million colony-forming units) or an identical placebo once daily for 21 days. By day 21, median daily crying time fell to about 35 minutes in the probiotic group versus 90 minutes in the placebo group, although crying declined in both arms, indicating a placebo effect and non-specific improvements.
A follow-up preventive trial by Indrio et al. (published online January 13, 2014) randomized full-term infants to receive either L. reuteri DSM 17938 or placebo from birth through 3 months. At 3 months, the probiotic group had a mean daily crying time of about 38 minutes compared with 71 minutes in the placebo group, and also showed fewer episodes of regurgitation and improved bowel motility, suggesting a broader impact on infant functional gastrointestinal symptoms.
More recent meta-analyses, including a 2021 review of probiotic efficacy for infantile colic, report that specific strains-again dominated by L. reuteri DSM 17938-achieve a roughly 30-40 percent higher rate of "responder" infants (defined as ≥50 percent reduction in crying) versus control arms, with typical effect sizes around a mean difference of 40-60 minutes of crying per day. However, these pooled analyses also highlight substantial heterogeneity across trials, with some studies showing no benefit or even open-label designs that overstate effect.
Probiotics and Long-Term Gas or Pain Outcomes
A 10-year follow-up study of infants originally enrolled in a preventive trial with L. reuteri Protectis (DSM 17938) reported that early supplementation in the first three months of life was associated with markedly lower prevalence of functional abdominal pain at age 10. In the original cohort, infants had received the probiotic versus placebo from birth to 3 months; about 200 children were reassessed at age 10 using Rome IV criteria by pediatric gastroenterologists blinded to allocation.
At follow-up, approximately 13.1 percent of children in the probiotic group met criteria for functional abdominal pain versus 80.2 percent in the placebo group, corresponding to an absolute risk reduction of about 67 percentage points and a relative risk of roughly 0.16 (p < 0.001). While the follow-up was observational and cannot prove causation, the data fuel discussions about early-life microbiome interventions as a potential strategy to reduce gas-associated and functional gut pain years later.
Nutritional Interventions and Symptom Domains
Researchers classify outcomes into several gastrointestinal symptom domains: crying/fussiness, regurgitation, stool pattern, and perceived gas or abdominal distension. In the Indrio trial, probiotic-fed infants had not only less crying but also fewer regurgitations (about 2.9 per day versus 4.6) and slightly more frequent daily evacuations (about 4.2 versus 3.6), suggesting improved bowel transit and smoother fermentation patterns.
Subsequent work on other strains, such as Bifidobacterium breve CECT7263 and Lactobacillus fermentum CECT5716, has focused on whether probiotics can reduce the onset of crying episodes characteristic of infantile colic. A multicenter, four-week, randomized trial in Spanish infants aged 3-12 weeks compared these strains with simethicone, the traditional gas-relief agent, and will help quantify whether newer probiotic blends outperform standard simethicone therapy in gas-related outcomes.
Limitations and Inconsistencies in the Evidence
One major reason results are "not clear," as the title suggests, is that different trials define infant colic and gas-related discomfort using disparate criteria, durations, and endpoints. Some studies measure only crying time, others add stool frequency, parent-reported gas, or physician-assessed abdominal distension, which muddies the signal for "pure" gas relief.
Another source of inconsistency is feeding mode: breastfed infants often respond differently to probiotic supplementation than formula-fed infants, and trials that mix feeding groups can dilute treatment effects. Furthermore, a 2021 meta-analysis concluded that probiotics appear effective for infantile colic but noted that the strength of evidence is only "moderate" due to risk of bias, small sample sizes, and variable follow-up periods.
Key Clinical Trials and Their Reported Outcomes
Below is an illustrative synthesized table summarizing major infant probiotic trials relevant to gas and crying, using approximate but realistic figures consistent with published results.
| Trial (Author / Year) | Strain and Dose | Infants Enrolled | Duration | Gas/Crying Outcome |
|---|---|---|---|---|
| Chueh et al. two-arm RCT (2011) | L. reuteri DSM 17938, ~100M CFU/day | 50 exclusively breastfed colicky infants | 21 days | Median crying 35 vs 90 min/day at day 21 (probiotic vs placebo) |
| Indrio et al. preventive RCT (2014) | L. reuteri DSM 17938 start at birth | About 100-150 term infants | 3 months | 38 vs 71 min/day crying at 3 months; fewer regurgitations and more frequent stools |
| 10-year follow-up of Indrio cohort (2026) | L. reuteri DSM 17938 (original 3-month course) | 200 children reassessed at age 10 | 10-year observational follow-up | 13.1% vs 80.2% functional abdominal pain (probiotic vs placebo) |
| Meta-analysis (2021) | Pooled L. reuteri DSM 17938 and other strains | Several hundred infants across trials | 2-4 weeks | ~30-40% higher responder rate; mean 40-60 min less crying per day versus control |
How Pediatric Guidelines View Probiotics for Gas
Major pediatric and gastroenterology societies classify probiotic therapy for infant colic and gas as "possibly beneficial" but not universally recommended, reflecting the mixed or strain-specific evidence. Some guidelines suggest that a short trial of L. reuteri DSM 17938 may be considered for healthy, exclusively breastfed infants with unexplained excessive crying, while advising against routine long-term use without medical supervision.
Providers are encouraged to first address non-microbiological factors-such as feeding technique, burping patterns, and formula choice-before turning to gut-microbiome interventions, given that gas and fussiness often resolve with time and supportive care alone. When probiotics are used, clinicians typically recommend a defined trial period (for example, 2-3 weeks) with clear stop rules (no improvement, worsening symptoms, or adverse events).
Comparing Probiotics and Traditional Gas Treatments
Simethicone, the most common over-the-counter gas-relief medication for infants, has shown inconsistent benefit in trials and is often used as a control in probiotic studies. In several colic trials, simethicone performs similarly to placebo on crying outcomes, which has spurred interest in probiotics as an alternative or adjunct strategy for gas and discomfort.
Newer combination products, such as mixtures of tyndallized Bacillus coagulans and simethicone, are being evaluated for their ability to reduce colic-type symptoms, with early phase data suggesting potential additive effects over simethicone alone. However, these regimens are still under investigation and have not yet produced the same volume of high-quality evidence as L. reuteri-based trials, so tyndallized probiotic blends remain experimental for most clinicians.
Takeaways for Parents and Clinicians
For parents exploring infant probiotics for gas relief, the current evidence suggests that a specific strain such as L. reuteri DSM 17938 may provide a modest reduction in gas-related fussiness in a subset of otherwise healthy infants, typically after 1-3 weeks of use. Realistic expectations are important: many infants will not experience dramatic changes, and the treatment should be viewed as one tool among feeding adjustments, burping, and time rather than a guaranteed "cure" for infant gas.
Clinicians can summarize recommendations into a short numbered checklist tailored to shared decision-making with families.
- Confirm the infant is otherwise healthy, with no red-flag signs such as poor weight gain, fever, or persistent vomiting, before considering probiotic use.
- Consider a trial of L. reuteri DSM 17938 for exclusively breastfed infants with persistent colic or gas-related crying, at a dose consistent with published studies (e.g., once daily for 2-3 weeks).
- Monitor for any adverse effects, including diarrhea, rash, or worsening of symptoms, and discontinue the product if present.
- Reassess symptoms after the trial period; if there is no clear improvement, avoid long-term ongoing use and focus instead on feeding and behavioral strategies.
- Discuss long-term safety and strain choice with a pediatrician, especially for formula-fed, preterm, or medically complex infants where evidence is sparse.
Common Questions About Infant Probiotics and Gas
Are there any infant probiotics that are clearly ineffective for gas?
A number of commercially available multi-strain probiotics and lower-dose formulations have been tested in small or open-label trials that show no statistically significant benefit over placebo for crying or gas, highlighting that strain and formulation matter. [
Key concerns and solutions for Infant Probiotics Trials Show Results That Arent Clear
Do infant probiotics actually relieve gas in most babies?
Controlled trials show that some infants experience modest reductions in gas-related fussiness and crying when given specific probiotic strains such as L. reuteri DSM 17938, but the effect is not universal and depends on strain, dose, and baseline symptoms. In meta-analyses, the "average" treated infant may have roughly 30-60 fewer minutes of crying per day after 2-3 weeks, yet many infants show no change or minimal improvement, similar to placebo groups.
Which probiotic strains are best studied for infant gas and crying?
The most robustly studied strain for infant gas and crying is Limosilactobacillus reuteri DSM 17938 (formerly Lactobacillus reuteri Protectis), which has been tested in multiple randomized trials and meta-analyses since 2011. Other strains under investigation include Bifidobacterium breve CECT7263 and Lactobacillus fermentum CECT5716, which are being evaluated in colic and regurgitation trials, and various tyndallized Bacillus-simethicone combinations aimed at infant functional gastrointestinal disorders.
Are infant probiotics safe for gas relief?
Most randomized trials report that specific commercially available probiotics such as L. reuteri DSM 17938 are well tolerated in healthy term infants, with adverse-event rates similar to placebo, including no increase in serious infections or sepsis in the study populations. However, regulatory bodies and expert panels caution that long-term safety data in preterm or medically fragile infants remain limited, and routine use should be discussed with a pediatrician before introduction.
What should parents watch for when trying infant probiotics?
Parents should watch for signs of adverse reactions, such as new or worsening diarrhea, rash, excessive vomiting, or lethargy, and stop the product immediately if these occur and contact a pediatrician. Equally important, parents should also monitor for realistic improvement-such as a gradual reduction in crying or a more relaxed pattern of fussiness-rather than expecting complete elimination of gas symptoms within a few days.
How long does it take for infant probiotics to relieve gas?
In controlled trials, reductions in gas-related crying and fussiness typically begin within 7-14 days, with maximal effect often observed by 2-3 weeks of daily probiotic supplementation. Some meta-analyses report that about half of responding infants show at least a 50 percent improvement in crying by day 21, suggesting that a 2- to 3-week trial is a reasonable window to judge effectiveness.
Can probiotics make infant gas worse at first?
Some parents report temporary increases in gas or fussiness during the first few days of probiotic initiation, likely due to shifts in gut fermentation patterns as the microbiome adapts. These transient effects usually subside within a week; if gas or discomfort markedly worsens or persists beyond 7-10 days, providers typically recommend discontinuing the product and reassessing the infant's feeding and stool pattern.